MedTrace Logo

Study of Pamidronate for the Prevention of Heterotopic Ossification

NCT00262392 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-03-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether Bisphosphonates in comparison to radiation therapy are effective in the prophylaxis and treatment of heterotopic ossification in high risk patients.

Conditions

Interventions

DRUG

Pamidronate (AREDIA)

Pamidronate (AREDIA) vs radiation

Sponsors & Collaborators

  • FAG (Freie Medizinische Gesellschaft)

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • philipp schuetz, MD · University Hospital, Basel, Switzerland

  • Christian Meier, MD · University Hospital in Basel

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262392 on ClinicalTrials.gov